Key Insights
The global arthritis therapeutics market, valued at approximately $XX million in 2025, is projected to experience robust growth, exhibiting a Compound Annual Growth Rate (CAGR) of 6.65% from 2025 to 2033. This expansion is driven by several key factors. The rising prevalence of arthritis, particularly osteoarthritis and rheumatoid arthritis, across aging populations worldwide significantly fuels market demand. Technological advancements leading to the development of more effective and targeted biologic therapies, such as TNF inhibitors and JAK inhibitors, are also contributing to growth. Furthermore, increased awareness of arthritis and improved access to healthcare, particularly in developing economies, are creating new opportunities for market expansion. The market is segmented by drug class (NSAIDs, DMARDs, Immunosuppressants, Biologics, Others) and route of administration (oral, parenteral, others), reflecting diverse treatment approaches and patient preferences. Major pharmaceutical companies like UCB Biosciences Inc, Otsuka Pharmaceutical, Bristol Myers Squibb (Celgene), Eisai Inc, AbbVie Inc, Sumitomo Dainippon Pharma Co, Johnson & Johnson, Sanofi S.A., and Pfizer Inc are key players, driving innovation and competition. North America currently holds a significant market share, driven by high healthcare expenditure and prevalence rates. However, Asia-Pacific is poised for substantial growth, fueled by increasing awareness and rising disposable incomes. Despite these positive trends, challenges remain, including high drug costs limiting accessibility, potential side effects of certain therapies, and the need for further research into disease-modifying treatments for specific arthritis types.
The market's future trajectory is influenced by several factors. The continued development and approval of novel biologics and targeted therapies will be crucial in shaping market growth. Furthermore, the focus on personalized medicine, tailoring treatment strategies to individual patient needs, will gain prominence. The increasing adoption of telemedicine and remote patient monitoring could enhance accessibility and improve treatment outcomes. Regulatory approvals and pricing policies will also play a significant role in determining market access and affordability. The market's competitive landscape is intense, with major pharmaceutical companies investing heavily in R&D and strategic partnerships to strengthen their market positions. The long-term outlook remains positive, with consistent growth anticipated driven by unmet medical needs and ongoing therapeutic advancements in the field of arthritis management.

Arthritis Therapeutics Industry Market Report: 2019-2033
This comprehensive report provides a detailed analysis of the Arthritis Therapeutics market, encompassing market dynamics, growth trends, regional dominance, product landscape, key players, and future outlook. The study period spans from 2019 to 2033, with 2025 serving as the base and estimated year. The report delves into the parent market of Pharmaceutical Industry and the child market of Arthritis Therapeutics. This report is invaluable for industry professionals, investors, and researchers seeking a thorough understanding of this rapidly evolving market. The market size is projected to reach xx Million units by 2033.
Arthritis Therapeutics Industry Market Dynamics & Structure
The global arthritis therapeutics market is characterized by a moderately concentrated landscape, with a few major players holding significant market share. Technological innovation, driven by advancements in biologics and targeted therapies, is a key driver. Stringent regulatory frameworks, particularly concerning drug approvals and safety, influence market dynamics. Competitive pressures arise from the availability of substitute treatments and the emergence of biosimilars. The end-user demographic is primarily comprised of aging populations with a high prevalence of arthritis, resulting in substantial demand. Mergers and acquisitions (M&A) activity is relatively frequent, reflecting strategic consolidation and expansion efforts.
- Market Concentration: Moderately concentrated, with top 5 players holding approximately xx% market share (2025).
- Technological Innovation: Focus on biologics, targeted therapies, and personalized medicine.
- Regulatory Framework: Stringent approvals and post-market surveillance impact time to market and costs.
- Competitive Substitutes: Over-the-counter pain relievers and alternative therapies pose competitive challenges.
- End-User Demographics: Aging population and rising prevalence of arthritis drive market growth.
- M&A Activity: Significant M&A activity observed in the historical period (2019-2024), with xx deals recorded, indicating a trend of consolidation.
Arthritis Therapeutics Industry Growth Trends & Insights
The arthritis therapeutics market exhibited a CAGR of xx% during the historical period (2019-2024) and is projected to grow at a CAGR of xx% during the forecast period (2025-2033). Market size evolution is primarily driven by increasing prevalence of arthritis, growing awareness, and improved access to healthcare. Adoption rates of newer, more effective therapies, particularly biologics, are increasing, while older treatments such as NSAIDs remain prevalent. Technological disruptions, such as the development of biosimilars and personalized medicine approaches, are reshaping the competitive landscape. Consumer behavior is shifting towards a preference for convenient, targeted therapies with fewer side effects. Market penetration of biologic agents is increasing steadily, while the penetration rate for NSAIDs has remained fairly stable.

Dominant Regions, Countries, or Segments in Arthritis Therapeutics Industry
North America currently holds the largest market share in the arthritis therapeutics market, driven by high healthcare expenditure, robust research and development activities, and a significant aging population. Within drug classes, Biologic Agents dominate the market owing to their superior efficacy in treating severe forms of arthritis. Oral route of administration remains the most preferred route, driven by patient convenience.
- Leading Region: North America (Market Share xx% in 2025).
- Key Drivers (North America): High healthcare expenditure, advanced healthcare infrastructure, strong R&D pipeline.
- Leading Drug Class: Biologic Agents (Market Share xx% in 2025).
- Leading Route of Administration: Oral (Market Share xx% in 2025).
- Growth Potential: High growth potential in emerging markets like Asia-Pacific due to rising prevalence of arthritis and increasing healthcare spending.
Arthritis Therapeutics Industry Product Landscape
The market offers a diverse range of products, including NSAIDs, DMARDs, immunosuppressants, and biologic agents, each with unique selling propositions. Biologic agents represent a significant advancement, offering targeted therapy with improved efficacy and reduced side effects compared to traditional treatments. Technological advancements focus on improving drug delivery mechanisms, enhancing efficacy, and minimizing adverse events.
Key Drivers, Barriers & Challenges in Arthritis Therapeutics Industry
Key Drivers:
- Increasing prevalence of arthritis globally.
- Growing geriatric population.
- Rising healthcare expenditure and improved access to healthcare.
- Technological advancements leading to development of novel therapies.
Challenges:
- High cost of biologic therapies, impacting affordability and accessibility.
- Stringent regulatory requirements prolonging drug development and approval processes.
- Intense competition from existing and emerging players, including biosimilars.
- Supply chain disruptions affecting drug availability and pricing.
Emerging Opportunities in Arthritis Therapeutics Industry
- Growing demand for personalized medicine approaches and targeted therapies.
- Expansion into untapped markets in emerging economies.
- Development of novel drug delivery systems to enhance efficacy and reduce side effects.
- Focus on preventative measures and early intervention strategies.
Growth Accelerators in the Arthritis Therapeutics Industry Industry
Long-term growth is propelled by continuous innovation in drug development, focusing on improved efficacy, safety, and convenience. Strategic collaborations between pharmaceutical companies and research institutions enhance the R&D pipeline. Expansion into emerging markets with high unmet medical needs offers significant growth potential. Furthermore, the development of biosimilars offers a more cost-effective treatment option, driving market expansion.
Key Players Shaping the Arthritis Therapeutics Industry Market
- UCB Biosciences Inc
- Otsuka Pharmaceutical
- Celgene Corporation (Bristol-Myers Squibb)
- Eisai Inc
- AbbVie Inc
- Sumitomo Dainippon Pharma Co
- Johnson & Johnson
- Sanofi S A
- Pfizer Inc
Notable Milestones in Arthritis Therapeutics Industry Sector
- September 2022: Significant long-term data from the KEEPsAKE trials demonstrated that over 50% of adult psoriatic arthritis patients treated with Skyrizi (risankizumab, 150mg) achieved a 90% reduction in the Psoriasis Area and Severity Index (PASI 90) and an American College of Rheumatology 20 (ACR20) response at 100 weeks.
- September 2022: The USFDA approved Deucravacitinib, an oral TYK2 inhibitor, for moderate-to-severe plaque psoriasis, potentially expanding its use in psoriatic arthritis.
In-Depth Arthritis Therapeutics Industry Market Outlook
The arthritis therapeutics market holds significant future potential, driven by continuous innovation, expanding patient populations, and increasing healthcare spending globally. Strategic opportunities lie in developing novel therapies, leveraging personalized medicine approaches, and penetrating emerging markets. The market is poised for continued growth, with a focus on improving treatment outcomes and enhancing patient quality of life.
Arthritis Therapeutics Industry Segmentation
-
1. Drug Class
- 1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 1.2. Disease-Modifying Antirheumatic Drugs (DMARDs)
- 1.3. Immunosuppressants
- 1.4. Biologic Agents
- 1.5. Other Drug Classes
-
2. Route of Administration
- 2.1. Oral
- 2.2. Parenteral
- 2.3. Other Routes of Administration
Arthritis Therapeutics Industry Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. Germany
- 2.2. United Kingdom
- 2.3. France
- 2.4. Italy
- 2.5. Spain
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
-
4. Middle East and Africa
- 4.1. GCC
- 4.2. South Africa
- 4.3. Rest of Middle East and Africa
-
5. South America
- 5.1. Brazil
- 5.2. Argentina
- 5.3. Rest of South America

Arthritis Therapeutics Industry REPORT HIGHLIGHTS
Aspects | Details |
---|---|
Study Period | 2019-2033 |
Base Year | 2024 |
Estimated Year | 2025 |
Forecast Period | 2025-2033 |
Historical Period | 2019-2024 |
Growth Rate | CAGR of 6.65% from 2019-2033 |
Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Increasing Prevalence of Psoriatic Arthritis Associated with Increasing Obesity; Strong Product Pipeline
- 3.3. Market Restrains
- 3.3.1. High Cost of Treatment
- 3.4. Market Trends
- 3.4.1. Immunosuppressants Segment is Expected to Hold a Large Share in the Market
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Arthritis Therapeutics Industry Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Drug Class
- 5.1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 5.1.2. Disease-Modifying Antirheumatic Drugs (DMARDs)
- 5.1.3. Immunosuppressants
- 5.1.4. Biologic Agents
- 5.1.5. Other Drug Classes
- 5.2. Market Analysis, Insights and Forecast - by Route of Administration
- 5.2.1. Oral
- 5.2.2. Parenteral
- 5.2.3. Other Routes of Administration
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Middle East and Africa
- 5.3.5. South America
- 5.1. Market Analysis, Insights and Forecast - by Drug Class
- 6. North America Arthritis Therapeutics Industry Analysis, Insights and Forecast, 2019-2031
- 6.1. Market Analysis, Insights and Forecast - by Drug Class
- 6.1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 6.1.2. Disease-Modifying Antirheumatic Drugs (DMARDs)
- 6.1.3. Immunosuppressants
- 6.1.4. Biologic Agents
- 6.1.5. Other Drug Classes
- 6.2. Market Analysis, Insights and Forecast - by Route of Administration
- 6.2.1. Oral
- 6.2.2. Parenteral
- 6.2.3. Other Routes of Administration
- 6.1. Market Analysis, Insights and Forecast - by Drug Class
- 7. Europe Arthritis Therapeutics Industry Analysis, Insights and Forecast, 2019-2031
- 7.1. Market Analysis, Insights and Forecast - by Drug Class
- 7.1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 7.1.2. Disease-Modifying Antirheumatic Drugs (DMARDs)
- 7.1.3. Immunosuppressants
- 7.1.4. Biologic Agents
- 7.1.5. Other Drug Classes
- 7.2. Market Analysis, Insights and Forecast - by Route of Administration
- 7.2.1. Oral
- 7.2.2. Parenteral
- 7.2.3. Other Routes of Administration
- 7.1. Market Analysis, Insights and Forecast - by Drug Class
- 8. Asia Pacific Arthritis Therapeutics Industry Analysis, Insights and Forecast, 2019-2031
- 8.1. Market Analysis, Insights and Forecast - by Drug Class
- 8.1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 8.1.2. Disease-Modifying Antirheumatic Drugs (DMARDs)
- 8.1.3. Immunosuppressants
- 8.1.4. Biologic Agents
- 8.1.5. Other Drug Classes
- 8.2. Market Analysis, Insights and Forecast - by Route of Administration
- 8.2.1. Oral
- 8.2.2. Parenteral
- 8.2.3. Other Routes of Administration
- 8.1. Market Analysis, Insights and Forecast - by Drug Class
- 9. Middle East and Africa Arthritis Therapeutics Industry Analysis, Insights and Forecast, 2019-2031
- 9.1. Market Analysis, Insights and Forecast - by Drug Class
- 9.1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 9.1.2. Disease-Modifying Antirheumatic Drugs (DMARDs)
- 9.1.3. Immunosuppressants
- 9.1.4. Biologic Agents
- 9.1.5. Other Drug Classes
- 9.2. Market Analysis, Insights and Forecast - by Route of Administration
- 9.2.1. Oral
- 9.2.2. Parenteral
- 9.2.3. Other Routes of Administration
- 9.1. Market Analysis, Insights and Forecast - by Drug Class
- 10. South America Arthritis Therapeutics Industry Analysis, Insights and Forecast, 2019-2031
- 10.1. Market Analysis, Insights and Forecast - by Drug Class
- 10.1.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- 10.1.2. Disease-Modifying Antirheumatic Drugs (DMARDs)
- 10.1.3. Immunosuppressants
- 10.1.4. Biologic Agents
- 10.1.5. Other Drug Classes
- 10.2. Market Analysis, Insights and Forecast - by Route of Administration
- 10.2.1. Oral
- 10.2.2. Parenteral
- 10.2.3. Other Routes of Administration
- 10.1. Market Analysis, Insights and Forecast - by Drug Class
- 11. North America Arthritis Therapeutics Industry Analysis, Insights and Forecast, 2019-2031
- 11.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 11.1.1 United States
- 11.1.2 Canada
- 11.1.3 Mexico
- 12. Europe Arthritis Therapeutics Industry Analysis, Insights and Forecast, 2019-2031
- 12.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 12.1.1 Germany
- 12.1.2 United Kingdom
- 12.1.3 France
- 12.1.4 Italy
- 12.1.5 Spain
- 12.1.6 Rest of Europe
- 13. Asia Pacific Arthritis Therapeutics Industry Analysis, Insights and Forecast, 2019-2031
- 13.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 13.1.1 China
- 13.1.2 Japan
- 13.1.3 India
- 13.1.4 Australia
- 13.1.5 South Korea
- 13.1.6 Rest of Asia Pacific
- 14. Middle East and Africa Arthritis Therapeutics Industry Analysis, Insights and Forecast, 2019-2031
- 14.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 14.1.1 GCC
- 14.1.2 South Africa
- 14.1.3 Rest of Middle East and Africa
- 15. South America Arthritis Therapeutics Industry Analysis, Insights and Forecast, 2019-2031
- 15.1. Market Analysis, Insights and Forecast - By Country/Sub-region
- 15.1.1 Brazil
- 15.1.2 Argentina
- 15.1.3 Rest of South America
- 16. Competitive Analysis
- 16.1. Global Market Share Analysis 2024
- 16.2. Company Profiles
- 16.2.1 UCB Biosciences Inc
- 16.2.1.1. Overview
- 16.2.1.2. Products
- 16.2.1.3. SWOT Analysis
- 16.2.1.4. Recent Developments
- 16.2.1.5. Financials (Based on Availability)
- 16.2.2 Otsuka Pharmaceutical
- 16.2.2.1. Overview
- 16.2.2.2. Products
- 16.2.2.3. SWOT Analysis
- 16.2.2.4. Recent Developments
- 16.2.2.5. Financials (Based on Availability)
- 16.2.3 Celgene Corporation (Bristol-Myers Squibb)
- 16.2.3.1. Overview
- 16.2.3.2. Products
- 16.2.3.3. SWOT Analysis
- 16.2.3.4. Recent Developments
- 16.2.3.5. Financials (Based on Availability)
- 16.2.4 Eisai Inc
- 16.2.4.1. Overview
- 16.2.4.2. Products
- 16.2.4.3. SWOT Analysis
- 16.2.4.4. Recent Developments
- 16.2.4.5. Financials (Based on Availability)
- 16.2.5 AbbVie Inc
- 16.2.5.1. Overview
- 16.2.5.2. Products
- 16.2.5.3. SWOT Analysis
- 16.2.5.4. Recent Developments
- 16.2.5.5. Financials (Based on Availability)
- 16.2.6 Sumitomo Dainippon Pharma Co
- 16.2.6.1. Overview
- 16.2.6.2. Products
- 16.2.6.3. SWOT Analysis
- 16.2.6.4. Recent Developments
- 16.2.6.5. Financials (Based on Availability)
- 16.2.7 Johnson & Johnson
- 16.2.7.1. Overview
- 16.2.7.2. Products
- 16.2.7.3. SWOT Analysis
- 16.2.7.4. Recent Developments
- 16.2.7.5. Financials (Based on Availability)
- 16.2.8 Sanofi S A
- 16.2.8.1. Overview
- 16.2.8.2. Products
- 16.2.8.3. SWOT Analysis
- 16.2.8.4. Recent Developments
- 16.2.8.5. Financials (Based on Availability)
- 16.2.9 Pfizer Inc
- 16.2.9.1. Overview
- 16.2.9.2. Products
- 16.2.9.3. SWOT Analysis
- 16.2.9.4. Recent Developments
- 16.2.9.5. Financials (Based on Availability)
- 16.2.1 UCB Biosciences Inc
List of Figures
- Figure 1: Global Arthritis Therapeutics Industry Revenue Breakdown (Million, %) by Region 2024 & 2032
- Figure 2: Global Arthritis Therapeutics Industry Volume Breakdown (K Unit, %) by Region 2024 & 2032
- Figure 3: North America Arthritis Therapeutics Industry Revenue (Million), by Country 2024 & 2032
- Figure 4: North America Arthritis Therapeutics Industry Volume (K Unit), by Country 2024 & 2032
- Figure 5: North America Arthritis Therapeutics Industry Revenue Share (%), by Country 2024 & 2032
- Figure 6: North America Arthritis Therapeutics Industry Volume Share (%), by Country 2024 & 2032
- Figure 7: Europe Arthritis Therapeutics Industry Revenue (Million), by Country 2024 & 2032
- Figure 8: Europe Arthritis Therapeutics Industry Volume (K Unit), by Country 2024 & 2032
- Figure 9: Europe Arthritis Therapeutics Industry Revenue Share (%), by Country 2024 & 2032
- Figure 10: Europe Arthritis Therapeutics Industry Volume Share (%), by Country 2024 & 2032
- Figure 11: Asia Pacific Arthritis Therapeutics Industry Revenue (Million), by Country 2024 & 2032
- Figure 12: Asia Pacific Arthritis Therapeutics Industry Volume (K Unit), by Country 2024 & 2032
- Figure 13: Asia Pacific Arthritis Therapeutics Industry Revenue Share (%), by Country 2024 & 2032
- Figure 14: Asia Pacific Arthritis Therapeutics Industry Volume Share (%), by Country 2024 & 2032
- Figure 15: Middle East and Africa Arthritis Therapeutics Industry Revenue (Million), by Country 2024 & 2032
- Figure 16: Middle East and Africa Arthritis Therapeutics Industry Volume (K Unit), by Country 2024 & 2032
- Figure 17: Middle East and Africa Arthritis Therapeutics Industry Revenue Share (%), by Country 2024 & 2032
- Figure 18: Middle East and Africa Arthritis Therapeutics Industry Volume Share (%), by Country 2024 & 2032
- Figure 19: South America Arthritis Therapeutics Industry Revenue (Million), by Country 2024 & 2032
- Figure 20: South America Arthritis Therapeutics Industry Volume (K Unit), by Country 2024 & 2032
- Figure 21: South America Arthritis Therapeutics Industry Revenue Share (%), by Country 2024 & 2032
- Figure 22: South America Arthritis Therapeutics Industry Volume Share (%), by Country 2024 & 2032
- Figure 23: North America Arthritis Therapeutics Industry Revenue (Million), by Drug Class 2024 & 2032
- Figure 24: North America Arthritis Therapeutics Industry Volume (K Unit), by Drug Class 2024 & 2032
- Figure 25: North America Arthritis Therapeutics Industry Revenue Share (%), by Drug Class 2024 & 2032
- Figure 26: North America Arthritis Therapeutics Industry Volume Share (%), by Drug Class 2024 & 2032
- Figure 27: North America Arthritis Therapeutics Industry Revenue (Million), by Route of Administration 2024 & 2032
- Figure 28: North America Arthritis Therapeutics Industry Volume (K Unit), by Route of Administration 2024 & 2032
- Figure 29: North America Arthritis Therapeutics Industry Revenue Share (%), by Route of Administration 2024 & 2032
- Figure 30: North America Arthritis Therapeutics Industry Volume Share (%), by Route of Administration 2024 & 2032
- Figure 31: North America Arthritis Therapeutics Industry Revenue (Million), by Country 2024 & 2032
- Figure 32: North America Arthritis Therapeutics Industry Volume (K Unit), by Country 2024 & 2032
- Figure 33: North America Arthritis Therapeutics Industry Revenue Share (%), by Country 2024 & 2032
- Figure 34: North America Arthritis Therapeutics Industry Volume Share (%), by Country 2024 & 2032
- Figure 35: Europe Arthritis Therapeutics Industry Revenue (Million), by Drug Class 2024 & 2032
- Figure 36: Europe Arthritis Therapeutics Industry Volume (K Unit), by Drug Class 2024 & 2032
- Figure 37: Europe Arthritis Therapeutics Industry Revenue Share (%), by Drug Class 2024 & 2032
- Figure 38: Europe Arthritis Therapeutics Industry Volume Share (%), by Drug Class 2024 & 2032
- Figure 39: Europe Arthritis Therapeutics Industry Revenue (Million), by Route of Administration 2024 & 2032
- Figure 40: Europe Arthritis Therapeutics Industry Volume (K Unit), by Route of Administration 2024 & 2032
- Figure 41: Europe Arthritis Therapeutics Industry Revenue Share (%), by Route of Administration 2024 & 2032
- Figure 42: Europe Arthritis Therapeutics Industry Volume Share (%), by Route of Administration 2024 & 2032
- Figure 43: Europe Arthritis Therapeutics Industry Revenue (Million), by Country 2024 & 2032
- Figure 44: Europe Arthritis Therapeutics Industry Volume (K Unit), by Country 2024 & 2032
- Figure 45: Europe Arthritis Therapeutics Industry Revenue Share (%), by Country 2024 & 2032
- Figure 46: Europe Arthritis Therapeutics Industry Volume Share (%), by Country 2024 & 2032
- Figure 47: Asia Pacific Arthritis Therapeutics Industry Revenue (Million), by Drug Class 2024 & 2032
- Figure 48: Asia Pacific Arthritis Therapeutics Industry Volume (K Unit), by Drug Class 2024 & 2032
- Figure 49: Asia Pacific Arthritis Therapeutics Industry Revenue Share (%), by Drug Class 2024 & 2032
- Figure 50: Asia Pacific Arthritis Therapeutics Industry Volume Share (%), by Drug Class 2024 & 2032
- Figure 51: Asia Pacific Arthritis Therapeutics Industry Revenue (Million), by Route of Administration 2024 & 2032
- Figure 52: Asia Pacific Arthritis Therapeutics Industry Volume (K Unit), by Route of Administration 2024 & 2032
- Figure 53: Asia Pacific Arthritis Therapeutics Industry Revenue Share (%), by Route of Administration 2024 & 2032
- Figure 54: Asia Pacific Arthritis Therapeutics Industry Volume Share (%), by Route of Administration 2024 & 2032
- Figure 55: Asia Pacific Arthritis Therapeutics Industry Revenue (Million), by Country 2024 & 2032
- Figure 56: Asia Pacific Arthritis Therapeutics Industry Volume (K Unit), by Country 2024 & 2032
- Figure 57: Asia Pacific Arthritis Therapeutics Industry Revenue Share (%), by Country 2024 & 2032
- Figure 58: Asia Pacific Arthritis Therapeutics Industry Volume Share (%), by Country 2024 & 2032
- Figure 59: Middle East and Africa Arthritis Therapeutics Industry Revenue (Million), by Drug Class 2024 & 2032
- Figure 60: Middle East and Africa Arthritis Therapeutics Industry Volume (K Unit), by Drug Class 2024 & 2032
- Figure 61: Middle East and Africa Arthritis Therapeutics Industry Revenue Share (%), by Drug Class 2024 & 2032
- Figure 62: Middle East and Africa Arthritis Therapeutics Industry Volume Share (%), by Drug Class 2024 & 2032
- Figure 63: Middle East and Africa Arthritis Therapeutics Industry Revenue (Million), by Route of Administration 2024 & 2032
- Figure 64: Middle East and Africa Arthritis Therapeutics Industry Volume (K Unit), by Route of Administration 2024 & 2032
- Figure 65: Middle East and Africa Arthritis Therapeutics Industry Revenue Share (%), by Route of Administration 2024 & 2032
- Figure 66: Middle East and Africa Arthritis Therapeutics Industry Volume Share (%), by Route of Administration 2024 & 2032
- Figure 67: Middle East and Africa Arthritis Therapeutics Industry Revenue (Million), by Country 2024 & 2032
- Figure 68: Middle East and Africa Arthritis Therapeutics Industry Volume (K Unit), by Country 2024 & 2032
- Figure 69: Middle East and Africa Arthritis Therapeutics Industry Revenue Share (%), by Country 2024 & 2032
- Figure 70: Middle East and Africa Arthritis Therapeutics Industry Volume Share (%), by Country 2024 & 2032
- Figure 71: South America Arthritis Therapeutics Industry Revenue (Million), by Drug Class 2024 & 2032
- Figure 72: South America Arthritis Therapeutics Industry Volume (K Unit), by Drug Class 2024 & 2032
- Figure 73: South America Arthritis Therapeutics Industry Revenue Share (%), by Drug Class 2024 & 2032
- Figure 74: South America Arthritis Therapeutics Industry Volume Share (%), by Drug Class 2024 & 2032
- Figure 75: South America Arthritis Therapeutics Industry Revenue (Million), by Route of Administration 2024 & 2032
- Figure 76: South America Arthritis Therapeutics Industry Volume (K Unit), by Route of Administration 2024 & 2032
- Figure 77: South America Arthritis Therapeutics Industry Revenue Share (%), by Route of Administration 2024 & 2032
- Figure 78: South America Arthritis Therapeutics Industry Volume Share (%), by Route of Administration 2024 & 2032
- Figure 79: South America Arthritis Therapeutics Industry Revenue (Million), by Country 2024 & 2032
- Figure 80: South America Arthritis Therapeutics Industry Volume (K Unit), by Country 2024 & 2032
- Figure 81: South America Arthritis Therapeutics Industry Revenue Share (%), by Country 2024 & 2032
- Figure 82: South America Arthritis Therapeutics Industry Volume Share (%), by Country 2024 & 2032
List of Tables
- Table 1: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Region 2019 & 2032
- Table 2: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Region 2019 & 2032
- Table 3: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Drug Class 2019 & 2032
- Table 4: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Drug Class 2019 & 2032
- Table 5: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Route of Administration 2019 & 2032
- Table 6: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Route of Administration 2019 & 2032
- Table 7: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Region 2019 & 2032
- Table 8: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Region 2019 & 2032
- Table 9: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 10: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 11: United States Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 12: United States Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 13: Canada Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 14: Canada Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 15: Mexico Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 16: Mexico Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 17: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 18: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 19: Germany Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 20: Germany Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 21: United Kingdom Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 22: United Kingdom Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 23: France Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 24: France Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 25: Italy Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 26: Italy Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 27: Spain Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 28: Spain Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 29: Rest of Europe Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 30: Rest of Europe Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 31: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 32: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 33: China Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 34: China Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 35: Japan Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 36: Japan Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 37: India Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 38: India Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 39: Australia Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 40: Australia Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 41: South Korea Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 42: South Korea Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 43: Rest of Asia Pacific Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 44: Rest of Asia Pacific Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 45: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 46: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 47: GCC Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 48: GCC Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 49: South Africa Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 50: South Africa Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 51: Rest of Middle East and Africa Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 52: Rest of Middle East and Africa Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 53: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 54: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 55: Brazil Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 56: Brazil Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 57: Argentina Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 58: Argentina Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 59: Rest of South America Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 60: Rest of South America Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 61: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Drug Class 2019 & 2032
- Table 62: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Drug Class 2019 & 2032
- Table 63: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Route of Administration 2019 & 2032
- Table 64: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Route of Administration 2019 & 2032
- Table 65: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 66: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 67: United States Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 68: United States Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 69: Canada Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 70: Canada Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 71: Mexico Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 72: Mexico Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 73: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Drug Class 2019 & 2032
- Table 74: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Drug Class 2019 & 2032
- Table 75: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Route of Administration 2019 & 2032
- Table 76: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Route of Administration 2019 & 2032
- Table 77: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 78: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 79: Germany Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 80: Germany Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 81: United Kingdom Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 82: United Kingdom Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 83: France Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 84: France Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 85: Italy Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 86: Italy Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 87: Spain Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 88: Spain Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 89: Rest of Europe Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 90: Rest of Europe Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 91: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Drug Class 2019 & 2032
- Table 92: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Drug Class 2019 & 2032
- Table 93: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Route of Administration 2019 & 2032
- Table 94: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Route of Administration 2019 & 2032
- Table 95: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 96: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 97: China Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 98: China Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 99: Japan Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 100: Japan Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 101: India Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 102: India Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 103: Australia Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 104: Australia Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 105: South Korea Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 106: South Korea Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 107: Rest of Asia Pacific Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 108: Rest of Asia Pacific Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 109: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Drug Class 2019 & 2032
- Table 110: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Drug Class 2019 & 2032
- Table 111: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Route of Administration 2019 & 2032
- Table 112: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Route of Administration 2019 & 2032
- Table 113: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 114: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 115: GCC Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 116: GCC Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 117: South Africa Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 118: South Africa Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 119: Rest of Middle East and Africa Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 120: Rest of Middle East and Africa Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 121: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Drug Class 2019 & 2032
- Table 122: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Drug Class 2019 & 2032
- Table 123: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Route of Administration 2019 & 2032
- Table 124: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Route of Administration 2019 & 2032
- Table 125: Global Arthritis Therapeutics Industry Revenue Million Forecast, by Country 2019 & 2032
- Table 126: Global Arthritis Therapeutics Industry Volume K Unit Forecast, by Country 2019 & 2032
- Table 127: Brazil Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 128: Brazil Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 129: Argentina Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 130: Argentina Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
- Table 131: Rest of South America Arthritis Therapeutics Industry Revenue (Million) Forecast, by Application 2019 & 2032
- Table 132: Rest of South America Arthritis Therapeutics Industry Volume (K Unit) Forecast, by Application 2019 & 2032
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Arthritis Therapeutics Industry?
The projected CAGR is approximately 6.65%.
2. Which companies are prominent players in the Arthritis Therapeutics Industry?
Key companies in the market include UCB Biosciences Inc, Otsuka Pharmaceutical, Celgene Corporation (Bristol-Myers Squibb), Eisai Inc, AbbVie Inc , Sumitomo Dainippon Pharma Co, Johnson & Johnson, Sanofi S A, Pfizer Inc.
3. What are the main segments of the Arthritis Therapeutics Industry?
The market segments include Drug Class, Route of Administration.
4. Can you provide details about the market size?
The market size is estimated to be USD XX Million as of 2022.
5. What are some drivers contributing to market growth?
Increasing Prevalence of Psoriatic Arthritis Associated with Increasing Obesity; Strong Product Pipeline.
6. What are the notable trends driving market growth?
Immunosuppressants Segment is Expected to Hold a Large Share in the Market.
7. Are there any restraints impacting market growth?
High Cost of Treatment.
8. Can you provide examples of recent developments in the market?
September 2022: Significant long-term data from the KEEPsAKE trials demonstrated that over 50% of adult psoriatic arthritis patients treated with Skyrizi (risankizumab, 150mg) achieved a 90% reduction in the Psoriasis Area and Severity Index (PASI 90) and an American College of Rheumatology 20 (ACR20) response at 100 weeks. These results indicate the effectiveness of Skyrizi in treating psoriatic arthritis.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million and volume, measured in K Unit.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Arthritis Therapeutics Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Arthritis Therapeutics Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Arthritis Therapeutics Industry?
To stay informed about further developments, trends, and reports in the Arthritis Therapeutics Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database



Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations

Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence